Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer

February 19th 2016

Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.

Searching for Possibilities, Hortobagyi Found Greatness

February 17th 2016

Gabriel N. Hortobagyi, MD, who has pioneered many clinical advances in the treatment of women with breast cancer, was honored in the Breast Cancer category with a 2015 Giants of Cancer CareÂ® award, a program that the IntellisphereÂ® Oncology Specialty Group launched to honor leaders in the field.

Breast Cancer Research Sheds New Light on HR-Positive Disease

February 16th 2016

Although metastatic breast cancer remains incurable for most women, recent research offers important new guidance for clinicians managing patients across the spectrum of advanced disease.

Immunology Biomarkers Taking Shape in Breast Cancer

February 15th 2016

The search for immune system biomarkers that could prove clinically useful in treating patients with breast cancer is yielding promising results, particularly in triple-negative subtypes.

ASCO Guideline Clarifies Biomarker Assay Use in Adjuvant Breast Cancer Care

February 8th 2016

ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.

FDA Grants Antibody-Drug Conjugate Breakthrough Designation in TNBC

February 5th 2016

Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.

Dr. Ingrid Mayer on Targeted Therapies in ER+ Breast Cancer

February 3rd 2016

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Prospects in the Management of Breast Cancer

February 2nd 2016

Immunotherapy in Breast Cancer

February 2nd 2016

Analyzing the Use of Eribulin in Metastatic Breast Cancer

February 2nd 2016

Neoadjuvant Treatment in Triple-Negative Breast Cancer

February 2nd 2016

Post-Adjuvant Breast Cancer Treatment

February 2nd 2016

Neoadjuvant Therapy for HER2+ Breast Cancer

February 2nd 2016

MARIANNE and BOLERO-1 Trial Results in Breast Cancer

February 2nd 2016

First-Line Treatment of HER2-Positive MBC

February 2nd 2016

Managing Mouth Sores in Patients with Breast Cancer

February 2nd 2016

Review of Clinical Data on Palbociclib in Breast Cancer

February 2nd 2016

The Role of Fulvestrant in Metastatic HR+ Breast Cancer

February 2nd 2016

Appropriate Duration of Endocrine Therapy in Breast Cancer

February 2nd 2016

Managing Luminal A and Luminal B Breast Cancer

February 2nd 2016